COVID-19 ワクチン接種後の血栓塞栓症に関する最新情報
Theocharis Anastasiou1, Elias Sanidas1, Thekla Lytra2
1Department of Cardiology, "Laiko" General Hospital, 11527 Athens, Greece.
Vaccines
|August 28, 2025
まとめ
COVID-19ワクチンは,特にアデノウイルスベクター型は,VITTのような稀な血栓塞栓性イベントと関連しています. しかし,メリットはリスクに優れており,mRNAワクチンは低血栓発生率を示しています.
科学分野:
- 免疫学
- ワクチン学
- トロンボシス 研究
背景:
- COVID-19 ワクチン接種は,特にアデノウイルスベクターワクチンの場合,血栓栓症に関する懸念を引き起こしています.
- VITT,ATE,VTEを含む血栓塞栓性合併症は稀ですが,ワクチン接種後には報告されています.
研究 の 目的:
- COVID-19 ワクチン接種後の血栓塞栓性および腎臓合併症の発生および特性を検討する.
- 異なるワクチンプラットフォームに関連した血栓性リスクを比較する.
- 現在の管理戦略とCOVID-19ワクチンの総合的なリスク・利益プロファイルを強調する.
主な方法:
- COVID-19 ワクチンおよび血栓塞栓症に関する研究の文献レビュー.
- 報告されたVITT,VTE,ATE,腎臓合併症の分析
- アデノウイルスベクトルとmRNAワクチンの間の血栓性リスクの比較分析.
主要な成果:
- 血栓塞栓性イベント (VTE,ATE,VITT) と稀な腎臓合併症は,COVID-19ワクチン接種後では珍しくありません.
- リスク要因には,年齢,性別,ワクチンの種類,および併発性疾患が含まれます.
- mRNAワクチンは,アデノウイルスベクターワクチンと比較して,重篤な血栓性イベントのリスクを有意に低下させています.
結論:
- 稀な血栓性合併症にもかかわらず,COVID-19ワクチンは重篤な病気と死亡率を予防するために不可欠です.
- 個別化されたリスク評価と迅速な管理が重要です.
- mRNAワクチンは,低血栓性リスクプロファイルのために好ましい.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Vaccinations
45.3K
Overview
45.3K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889


